Southbreeze: For you to dismiss dilution as a legitimate

New Post Public Reply Private Reply Replies (5) Message Board
Daveludlow SouthBreeze #6207
Southbreeze: For you to dismiss dilution as a legitimate concern for AMBS shareholders is incredibly naive! We are a small bio-med penny stock. Did you not know that dilution was one of the major dangers facing the shareholders of such stocks? To think AMBS is shielded from this danger is plain ignorant.

The same things Gerald is saying about why we need this second billion shares (Hostile take overs, acquisitions, spin offs, etc) are all things he said when he raised the authorized shares to one billion in 2013. What percentage of the dilution we've experienced over the past 18 months has gone for those issues and what percentage has gone to simply fund the company? That's a legitimate point to be considered.

Some say dilution is just a fact of life for small penny stock biomeds. Yes, "some" dilution is. It is the responsibility of shareholders to keep a watchful eye on management and question them when dilution flags are appearing. Some here on this board have drunk so much AMBS Kool Aid that to question management is akin to blasphemy! Honestly, this mb has become almost like a religious cult to the point where if someone dares to question the company.....the board pounces on them.

I pounce on obvious bashers all the time! So what goes around comes around. I get it. But I'm no obvious basher, I'm an obvious long. For others on the mb not to realize that and think I am "soft bashing" shows they are severely lacking in perception and critical thinking.

Management doesn't worry about dilution in the same way shareholders do. My family's 1.1 million shares represents hard earned money. Management has millions of shares given to them as part of their compensation package. When someone owns 6 million shares instead of 500,000 shares, dilution doesn't really matter as much because no matter how much dilution there is....as long as the stock does reasonable well, they will still be worth multiple millions! Not so for the little guy.

I am a long. I believe in AMBS science. I am first about LymPro revenue, second about MANF's endless potential down the road, and third....I believe everything else is gravy. (Eltoprazine & Phenoguard). I'm no biotech expert, (and neither is the guy with that alias) but I've been around the small bio med business long enough to know 3 things:

1) Biotech Management has to engage in "sausage" making. (What goes on behind the scenes is not something shareholders would be happy about if they fully knew) This is just reality. Most small bio-techs don't realize their dreams, neither do most new drugs.

2) Biotechs Dilute to Keep their Dreams Alive. They have to. Big Pharma don't treat them kindly or try to help them out.....BP hopes AMBS fails.

3) Some Small Biotechs Make it Incredibly Big!! But those who do are a relatively small percentage of the total.

These 3 things I've learned have made me question every stock I'm in. I don't view management as though they were God's representatives. To be safe, I view them as God's competitor's representatives. This is not personal, it's just business. IMHO, when shareholders stop questioning management because they are in love with the dream management has created about how how rich they'll all become....that is when really bad things can happen to shareholders.

This mb would be better served if it were more tolerant of questions about what management is doing rather than 95% of all posts being about how wonderful MANF is!!!!!!! We get it. MANF is wonderful. But what if we only posted that 50% of the time, and the other 50% we discussed legitimate concerns? Not concerns raised by obvious bashers and flippers like Solantey and such, but coming from legitimate longs.

I think Gerald and management need to hear from shareholders about their real concerns. The Shareholder Meeting would be a good place for voicing some of those honest concerns. Unlike Warp, I thought the gentleman who pressed Gerald on those 5 questions during the CC was right on!! Warp writes off discussion about concerns as anxious "hand wringing" and the cause of "sleepless nights" that only the poor engage in, who really shouldn't be invested in this type of stock in the first place. I thought the gentleman asking the questions on the CC was respectful, but earnest. Sending Gerald messages all the time about how much we all admire him is not what he really needs. He's the CEO managing our investment. He needs to hear from us. We need to discuss issues seriously...not just dream of how rich we'll be.

Gerald needs to know that his credibility is on the line over the way he has mismanaged expectations. At the Jan. Conference in SF he said we wouldn't be pursuing a LymPro partner in the immediate future because of the "codes" they found that had increased the Net Present Value of LymPro multiple times! We haven't really heard about those "codes" since and we are trading at less than we were in January when he announced it!

Several months after January Gerald stated they had "identified" a LymPro Partner which would be announced at the end of summer. I think most of us anticipated it would be a "classic partner" with up front money. So when he tweeted that Friday afternoon about how excited he was over the news the next week....it was a real shock that Monday morning when we got a "master service agreement" with ICON rather than a "Classic Partnership" with J&J with 40 million dollars up front!!! These two examples I've mentioned, along with the data debacle during the July Conferences are examples of how Gerald has not managed expectations or executed flawlessly. (Not that I want him replaced)

At the beginning of the year his goal was to up list in Q2 of 2014. Now we are hearing Q1 2015. People have criticized me for worrying too much about the short term pps. They think I need reminding that this is a long term investment. I get it. All I am saying is that until more shareholder value is created....management should no leverage our shares with a billion additional shares! There's no good reason for doing a billion shares now, not when we're trading at .10 cents in mid September.

To not discuss these concerns on this mb and not raise them with management, but simply let them double the AS shares without even a peep from us.....is nothing more than Kool Aid drinking insecurity!!

I hope as participants in this mb we can mature into something more. We are the owners of AMBS and we need to intelligently raise our voice to management on an ongoing basis, so that together we can realize the incredible potential AMBS has!

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lindian's Bold Leap into Rare Earths Processing

Updated Category News Views 2

Changing the Game in Rare Earths When Lindian Resources announces a partnership, it's not just window dressing. This time, they've linked arms with Carester SAS for a hefty venture into oxide separation. The scope? An 8,000-tonne REO facility in Kazakhstan, a place already stamped as a geological treasure chest. We're staring at what could potentially be a new dawn for...

Continue Reading
Baystate Noble Plans Major ED Expansion for Future Needs

Updated Category News Views 2

A Trusted Name in Healthcare Steps Up When a healthcare player like Baystate Health decides to jump into the deep end with an expansion project, you know they're not just doodling on napkins. With a legacy stretching back to 1883, Baystate Health, anchored deeply in western New England, isn't just expanding for fun—it's a move to cement its position as a crucial...

Continue Reading
Mammotome Ramps Up to Tackle Biopsy Needle Shortage

Updated Category News Views 0

A Needle in High Demand There's no beating around the bush: we're staring at a breast biopsy needle shortage that's tossing the healthcare sector into a tizzy. It’s a sterner cocktail when you think that the procedure's delay isn't just a procedural hiccup. It’s a nerve-wracking limbo for patients teetering on the edge of a potential cancer diagnosis. That's where...

Continue Reading
Qapture Expands Global DeFi Reach with Key Acquisitions

Updated Category News Views 6

Qapture Investments just made a move in the digital finance space that's promising to turn some heads. From acquiring Flammarion Partners to snapping up Hermetik Trading's DeFi strategies, this Bermuda-based investment manager isn't here to play. Led by Frederick Pye, the firm's gearing up for an industry takeover by blending regulation with innovative digital finance...

Continue Reading
Flotek Faces Lawsuit: Investors Urged to Act Fast

Updated Category News Views 3

Flotek's Current Storm: Gather Your Wits, Shareholders If you've staked your hard-earned cash into Flotek Industries, Inc. (FTK), it's high time to buckle up. Those court-blaring sirens aren’t a drill: we're talking class-action territory, people. The Law Offices of Howard G. Smith sound the alarm, calling on investors who’ve had their financial feathers singed to...

Continue Reading
Northern CA Super Lawyers Honor Madigan & Lewis LLP

Updated Category News Views 3

Madigan & Lewis Surges with Prestigious Lawyer Recognitions There are firms that talk the talk, and then there's Madigan & Lewis blowing everyone off the water in Northern California's legal scene. Don't take my word for it—five of their attorneys just got the nod from Super Lawyers in a year brimming with competition. That's no small feat, and it marks them as a...

Continue Reading
Globant Unleashes MuleSoft AI Pod for Faster Integration

Updated Category News Views 0

Unlocking the AI Puzzle: Webinar Speed Dials You ever swim through a mash-up of tech lingo that makes you feel like you're trudging through waist-high molasses? Well, Saddle up because that's exactly where Globant's new MuleSoft AI Pod is heading. Through Glob.AI, they're going all in on turning what used to take months into mere weeks—finally, right? In the business of...

Continue Reading
ITP Media's Bold Move: Ready for Asian Market Surge

Updated Category News Views 3

Pushing Boundaries: ITP Media Group Eyes Asia ITP Media Group isn't here to tiptoe around the media market; they're diving headfirst with the recent takeover of Heart Media Group. A bold move, some might say, in this volatile world of media mergers and acquisitions. But let's break down what this really means. A Strategic Bet on Luxury To start, ITP Media is beefing up...

Continue Reading
TPx Pivots Post-Bankruptcy, Rebuilding for New Growth

Updated Category News Views 15

TPx Rebounds with Stronger Foundation Folks, TPx just got itself a fresh pair of legs to stand on. Emerging from the labyrinth of Chapter 11 bankruptcy, TPx has managed to shave off a cumbersome load of debt and cement a pathway to long-term success. A court nod from the U.S. Bankruptcy Court for the Southern District of Texas confirmed their reorganization plan. It's a...

Continue Reading
Joseph Spine Opens New Regenerative Therapy Center

Updated Category News Views 1

Regenerative Medicine: A New Frontier in Spine Care When spine care gets a facelift, you take notice. Joseph Spine Institute, a heavyweight in the spine care game, just threw hat into the regenerative ring. We're talking about using a patient's own cells to mend what's broken—that's advanced. They're launching a Regenerative Therapy Center in Tampa, ready to offer these...

Continue Reading

Top 5 Most Recently Viewed Articles

Annex Brands Names Ryan Heine as New Executive VP

Updated Category News Views 11

Annex Brands: A Strategic Shift in Leadership Here's a name you might be hearing more of in the franchise sphere: Ryan Heine. Elevated to the role of Executive Vice President at Annex Brands, this longtime insider is stepping up to play an even bigger part in the company's ambition to stretch its arms wider across North America. From Seeds to Branches: Heine's Journey...

Continue Reading
Deep Sky Advances Global Carbon Tech with $40M Bill Gates Boost

Updated Category News Views 181

Deep Sky's Innovative Carbon Capture Initiative Deep Sky, a trailblazing Canadian startup, is making significant strides in the realm of carbon removal. The company has recently completed the construction of what they refer to as the first-ever dedicated test hub for direct air capture (DAC) technologies, located in Alberta. This state-of-the-art Alpha facility has...

Continue Reading
Understanding Market Trends: A Look at Synopsys Short Interest

Updated Category News Views 178

Understanding the Market Sentiment Towards Synopsys Synopsys's short interest has seen a notable decline of 20.09% since the latest reporting. Currently, around 3.24 million shares are sold short, representing about 1.75% of the available shares for trading. Given the current trading volume, it would take approximately 3.14 days for traders to cover their short positions...

Continue Reading
Global Renters Insurance Market Set to Double in 10 Years

Updated Category News Views 193

Exploring the Rapid Expansion of the Renters Insurance Market The global renters insurance market is thriving, underpinned by a surge in consumer awareness regarding tenant risk protection and increasing adoption of digital insurance platforms. Individuals are increasingly investing in renters insurance as it offers financial security, liability coverage, and safeguards...

Continue Reading
Innovations in Canada's Pharmaceutical Packaging Industry by 2034

Updated Category News Views 186

Understanding the Canada Pharmaceutical Packaging Market In today's rapidly evolving healthcare landscape, the Canada pharmaceutical packaging market is set to witness significant growth. Forecasted to expand from USD 7.53 billion to USD 14.43 billion, this trajectory highlights the increasing importance placed on packaging solutions for pharmaceuticals, driven primarily...

Continue Reading